No attachments available.
2-PAM Autoinjectors Project Bioshield
Contact and place of performance
Erin Greninger, Contracting Officer
Washington, DC 20024
USA
This is a presoliciation notice for the following:
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.
The Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA) have issued this presolicitation notice for the 2-PAM Autoinjectors Project BioShield. The agency seeks the late-stage clinical development and regulatory approval of 2-PAM autoinjectors as a drug/device combination product designed to treat adult and pediatric populations for organophosphate poisoning, including nerve agents. This requirement includes the procurement of these autoinjectors for the Strategic National Stockpile (SNS) and the CHEMPACK Program.
The primary place of performance is Washington, DC, and the response deadline for solicitation 75A50126R00002 is June 16, 2026. This acquisition is categorized under NAICS 541714 for Research and Development in Biotechnology (except Nanobiotechnology) and PSC AB12 for Community and Regional Development R&D Services; Community Development; Applied Research. No set-aside has been designated for this project.
Erin Greninger serves as the Contracting Officer for this notice, which was published and updated on June 2, 2026. As of the publication date, there are no attachments associated with this notice. Potential respondents are tasked with meeting the requirements for both the development and delivery of medical countermeasures to enhance chemical defense capabilities.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.